Maxwell Life Sciences IPO Details
Maxwell Life Sciences IPO Summary
Maxwell Life Sciences IPO DRHP (Draft Red Herring Prospectus) has been Offer Document Returned.
Maxwell Life Sciences IPO total issue size comprises 66,99,600 shares . This includes a fresh issue of 56,49,600 shares . Offer for Sale consists of 10,50,000 shares . Pre-issue shareholding stands at 1,55,55,552, which will increase to 2,12,05,152 post-issue.
Maxwell Life Sciences IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
The Lead Managers for Maxwell Life Sciences IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Corporate Professionals Capital Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Maxwell Life Sciences DRHP.
Maxwell Life Sciences IPO Details
Maxwell Life Sciences IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| To be announced | |||
Maxwell Life Sciences IPO Reservation
Promoter Holding
Documents
Maxwell Life Sciences IPO Valuations
Maxwell Life Sciences Financial Information
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 78.32 | 60.76 | 56.28 | 38.66 |
| Revenue | 95.67 | 81.86 | 47.12 | 29.18 |
| Profit After Tax | 8.51 | 4.67 | 0.72 | -0.20 |
| Net Worth | 20.14 | 11.63 | 6.96 | 6.24 |
| Reserves and Surplus | 16.25 | 7.74 | 3.07 | 2.35 |
| Total Borrowing | 20.82 | 19.97 | 15.79 | 15.02 |
| Amount in ₹ Crore | ||||
About Maxwell Life Sciences IPO
Incorporated in 2004, Maxwell Life Sciences Ltd manufactures pharmaceutical formulations for tablets, capsules, syrups, ointments, creams, liquid orals, dry syrups, and powders.
Its product portfolio comprises more than 150 formulations, including Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Antacid, Anti-Ulcerants, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics, Anti-Fungal and anti-amoebic products.
The company's manufacturing facility is located at Boisar, Maharashtra, across 1,510 square meters, with the capability to produce 180 crore tablets per year, 60 crore capsules per year, 1.80 crores bottles of syrup per year and 1.80 crores tubes of ointment per year.
Its manufacturing process is approved by the World Health organization (WHO) for Good Manufacturing Practices (GMP) and Good Laboratory process (GLP) certification issued by Food & Drugs Administration, Maharashtra.
The company supplies pharmaceutical formulations to private companies, merchant exporters, and the government contracts. Under contract manufacturing, it produces pharmaceutical formulations for private companies or parties, which then market and distribute the products under their brand names, both in the domestic and international markets.
Additionally, it also supplies medicines to government hospitals, departments, public sector units, the armed forces, and other public entities.
Competitive Strengths
- Wide range of product offerings
- Experienced promoters and management
- Scalable Business Model
- Quality assurance
Strength Of Maxwell Life Sciences IPO
Risk Of Maxwell Life Sciences IPO
Objectives Maxwell Life Sciences IPO
1. Upgradation / Construction of the existing premises
2. Funding capital expenditure requirements for the purchase of plant & machinery and furniture & fixtures
3. Funding capital expenditure towards establishment of new office premise with interior works and utilities
4. To meet working capital requirements of our Company
5. Repayment/prepayment, in part or full, of certain of our borrowings
6. General Corporate Purposes
Company Contact Details
Maxwell Life Sciences
Office No. 5,
Target Mall Chandrvarker Road,
Borivali West, Mumbai
Mumbai, Maharashtra
Phone: +91-022-45227279
Email: compliance@mlspl.in
Website: http://www.mlspl.in/
Registrar Contact Details
Market Maker
Maxwell Life Sciences FAQs
The Maxwell Life Sciences IPO is a SME public issue comprising 6699600 equity shares with a face value of ₹10 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the BSE
As of now, the current GMP stands at TBA.
Quick Links
Comments
